Loading... Please wait...
Sort by:

therapy-trends-jpg.jpg
Therapy Trends
reports deliver critical and unbiased intelligence derived from in-depth interviews with the world’s foremost thought leaders on the current and future treatment landscapes in major disease areas. Research is focused on the major battlegrounds for market share and answers critical business questions about potential product positioning and competitiveness. Through continuous monitoring and frequent re-engagement with stakeholders, the FirstWord Therapy Trends analyst team delivers quarterly updates with each report ensuring insights remain current and relevant.

  • Therapy Trends KOL Insight: Pancreatic Cancer [2019]
    Learn More Therapy Trends KOL Insight: Pancreatic Cancer [2019]
    Are innovative modalities set to transform pancreatic cancer? Pancreatic cancer (PC) is widely regarded as the world's most lethal malignancy. Though outcomes have improved modestly with resection and adjuvant...
  • Therapy Trends KOL Insight: Migraine [2019]
    Learn More Therapy Trends KOL Insight: Migraine [2019]
    How will anti-CGRP monoclonal antibodies influence the current treatment paradigm? Significant unmet needs exist in the migraine market as a high percentage of patients do not respond to current treatments. Key opinion...
  • Therapy Trends KOL Insight: Targeted Therapies in Asthma [2019]
    Learn More Therapy Trends KOL Insight: Targeted Therapies in Asthma [2019]
    Will new biologics stoke up competition in the targeted asthma treatment landscape? Recent years have witnessed a rapid expansion in targeted treatments for severe asthma, and the landscape continues to evolve. Near...
  • Therapy Trends KOL Insight: Acute Lymphoblastic Leukaemia [2018]
    Learn More Therapy Trends KOL Insight: Acute Lymphoblastic Leukaemia [2018]
    How are CAR-T and monoclonals reshaping the ALL treatment landscape? Recent high-profile approvals for the CAR-T therapy Kymriah, and monoclonal antibodies Blincyto and Besponsa have reignited interest in ALL. Do these...
  • Therapy Trends KOL Insight: Multiple Sclerosis [2018]
    Learn More Therapy Trends KOL Insight: Multiple Sclerosis [2018]
    How is Ocrevus reshaping the MS treatment landscape? Oral disease modifying therapies have changed the way MS is treated, but what does the future hold for these agents? Key opinion leaders (KOLs) discuss how these...
  • Therapy Trends KOL Insight: Malignant Melanoma [2018]
    Learn More Therapy Trends KOL Insight: Malignant Melanoma [2018]
    What developments are on the horizon for malignant melanoma? The introduction of novel targeted systemic therapies has provided clinicians with valuable interventions for the treatment of malignant melanoma, however...
  • Therapy Trends KOL Insight: Prostate Cancer [2018]
    Learn More Therapy Trends KOL Insight: Prostate Cancer [2018]
    How will established and emerging agents reshape the prostate cancer treatment landscape? A plethora of novel therapies have been approved for prostate cancer over the past ten years, but what does the future hold? Key...
  • Colorectal Cancer: KOL Insight [2018]
    Learn More Colorectal Cancer: KOL Insight [2018]
    Are immunotherapies set to revolutionise the treatment of colorectal cancer? Available therapies for metastatic colorectal cancer (mCRC) prolong survival by nearly three years, but for most patients, treatment...
  • Non-Hodgkin’s Lymphoma: KOL Insight [2018]
    Learn More Non-Hodgkin’s Lymphoma: KOL Insight [2018]
    What impact will CAR-T therapies have on the NHL treatment landscape? The non-Hodgkin’s lymphoma (NHL) treatment armamentarium has been dominated by rituximab-based chemotherapy regimens for over a decade. Last...
  • Duchenne Muscular Dystrophy: KOL Insight [2018]
    Learn More Duchenne Muscular Dystrophy: KOL Insight [2018]
    How are gene therapies expected to revolutionise the treatment of Duchenne Muscular Dystrophy? Duchenne muscular dystrophy (DMD) is a devastating and fatal neuromuscular genetic disease with no known cure and few...
  • Diabetes Mellitus: Early Stage Outlook [2018]
    Learn More Diabetes Mellitus: Early Stage Outlook [2018]
    Are novel technologies set to revolutionise diabetes?  Diabetes is a chronic disease that requires lifelong management; however, rapid developments in innovative diabetes technologies (D-tech) have greatly improved...
  • Non-Small Cell Lung Cancer: KOL Insight [2018]
    Learn More Non-Small Cell Lung Cancer: KOL Insight [2018]
    What are the next key opportunities for growth of IOs in NSCLC? The growth of IO in NSCLC continues unabated. As Merck & Co.'s Keytruda becomes increasingly dominant in the first-line metastatic setting, will it be...
  • Chronic Lymphocytic Leukaemia: KOL Insight [2018]
    Learn More Chronic Lymphocytic Leukaemia: KOL Insight [2018]
    How will targeted therapy combinations transform the treatment of CLL? Chemoimmunotherapy regimens incorporating Rituxan/MabThera have traditionally been the cornerstone of CLL treatment. How is this expected to change?...
  • Atopic Dermatitis: KOL Insight [2018]
    Learn More Atopic Dermatitis: KOL Insight [2018]
    Will new pipeline therapies transform the treatment of atopic dermatitis? New pipeline agents look set to transform the treatment of moderate-to-severe atopic dermatitis. Dupixent (dupilumab; Regeneron/Sanofi) has...
  • Bladder Cancer: KOL Insight [2018]
    Learn More Bladder Cancer: KOL Insight [2018]
    How can immune checkpoint inhibitors differentiate themselves in the competitive Bladder cancer space? Five PD-1/PD-L1 immune checkpoint inhibitors are approved for bladder cancer, but how are these therapies faring on...
  • Psoriasis: KOL Insight [2018]
    Learn More Psoriasis: KOL Insight [2018]
    How will next-generation biologics change the psoriasis treatment landscape?  The treatment of psoriasis is evolving and the range of therapies is set to diversify with the approval and introduction of novel...

customer.service@firstwordpharma.com

All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved